Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Yale University
- Study ID
- NCT05907629
- Status
- Recruiting
Conditions
- Intracranial Atherosclerotic Stenosis (ICAS)
- Stroke
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- MRI — OTHERAdditional MRI to the CAPTIVA study at baseline and 12 months follow-up
Study Details
CAPTIVA-MRI is an observational multimodal MR imaging study that is ancillary to the CAPTIVA trial \[a 3-arm, double-blind Phase III trial conducted at approximately 115 StrokeNet sites randomizing patients with stroke attributed to 70-99% intracranial atherosclerotic stenosis (ICAS) to aspirin plus ticagrelor, clopidogrel, or rivaroxaban.\] The primary goal of this ancillary study is to determine if MRI biomarkers can potentially identify ICAS patients who fail best medical management. The CAPTIVA-MRI study leverages the CAPTIVA trial design and implementation to capture information that will inform and facilitate the next generation of ICAS trials and the management of patients with ICAS.
Key Dates
- Start date
- Jun 24, 2024
- Status verified
- Aug 2025
- Primary completion
- Mar 31, 2029
- Completion
- Mar 31, 2029
Study Design
- Enrollment
- 300 participants (estimated)
Arms
- Arm: CAPTIVA-MRI GroupCAPTIVA patients with stroke attributed to 70-99% intracranial atherosclerotic stenosis (ICAS) to aspirin plus ticagrelor, clopidogrel, or rivaroxaban.
Primary Outcome Measure
Establish ICAS hemodynamic and plaque MRI biomarkers as reliable predictors of recurrent ischemic stroke in the vascular territory of the index stroke. [ Time Frame: 12 months ]
Central Contacts
- Ka-Ho Wong801-585-7575
- Amy Sulken
Locations (13)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Alabama Hospital | Birmingham | Alabama | 35233 | Ekaterina Bakradze (PRINCIPAL_INVESTIGATOR) |
| Yale New Haven Hospital | New Haven | Connecticut | 06510 | James Giles (PRINCIPAL_INVESTIGATOR) |
| MedStar Washington Hospital Center | Washington D.C. | District of Columbia | 20010 | Sana Somani (PRINCIPAL_INVESTIGATOR) |
| Baptist Medical Center Jacksonville | Jacksonville | Florida | 32207 | Jefferson Atillo Melissa Stratoberdha Ricardo Hanel (PRINCIPAL_INVESTIGATOR) |
| Jackson Memorial Hospital, Miami | Miami | Florida | 33136 | Iszet Campo-Bustillo Victor Del Brutto (PRINCIPAL_INVESTIGATOR) |
| SIH Memorial Hospital of Carbondale | Carbondale | Illinois | 62901 | Andrea Loggini (PRINCIPAL_INVESTIGATOR) |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | Tareq Kass-Hout (PRINCIPAL_INVESTIGATOR) |
| University of Illinois Hospital | Chicago | Illinois | 60612 | Ali Alaraj, MD (PRINCIPAL_INVESTIGATOR) |
| Barnes Jewish Hospital | St Louis | Missouri | 63108 | Alyssa Hiserote Jill Newgent Yan Wang, MD (PRINCIPAL_INVESTIGATOR) |
| Buffalo General Medical Center | Buffalo | New York | 14203 | Annemarie Crumlish Amit Kandel (PRINCIPAL_INVESTIGATOR) |
| North Shore University Hospita | Manhasset | New York | 11030 | Ayesha Rehman Rohan Arora (PRINCIPAL_INVESTIGATOR) |
| Carolinas Medical Center | Charlotte | North Carolina | 28203 | Rahul Karamchandani (PRINCIPAL_INVESTIGATOR) |
| UH Cleveland Medical Center | Cleveland | Ohio | 44106 | Sepideh Amin-Hanjani (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Birmingham, AL
Related Studies
- Evaluation of an Advanced Lower Extremity NeuroprosthesesRecruiting · Case Western Reserve University · Cleveland, Ohio
- Genetic and Environmental Risk Factors for Hemorrhagic StrokeRecruiting · State University of New York at Buffalo · Chicago, Illinois
- Quality Improvement and Practice Based Research in Neurology Using the EMRPHASE4 · Enrolling By Invitation · Endeavor Health · Evanston, Illinois
- Neurologic Stem Cell Treatment StudyRecruiting · MD Stem Cells · Westport, Connecticut